High-throughput detection of neutralizing antibodies to SARS-CoV-2 variants using flow cytometry

Xiaohan Zhang,Yajie Wang,Mansheng Li,Haolong Li,Xiaomei Zhang,Xingming Xu,Di Hu,Te Liang,Yunping Zhu,Yongzhe Li,Bingwei Wang,Xiaobo Yu

DOI: https://doi.org/10.1101/2023.08.07.23293304

2024-05-10

Abstract:Detecting neutralizing antibodies (NAbs) to SARS-CoV-2 variants is crucial for controlling COVID-19 spread. We developed a high-throughput assay for the broad systematic examination of NAbs to eleven SARS-CoV-2 variants, which include D614G, Alpha, Beta, Gamma, Delta, Kappa, and Omicron sub-lineages BA.1-BA.5. The assay is cost-effective, reliable, 35-fold more sensitive than Luminex technology, and can include new variants during SARS-CoV-2 evolution. Importantly, our results highly correlated with a commercial IgG serological assay (R = 0.89), the FDA-approved cPass sVNT assay (R = 0.93), pseudivirus-based neutralizing assay (R = 0.96, R = 0.66, R = 0.65) and live virus based neutralization assay (R = 0.79, R = 0.64) . Using this platform, we constructed a comprehensive overview of the interactions between SARS-CoV-2 variants’ Spike trimer proteins and ACE2 receptors, and identified a polyclonal Ab with broad neutralizing activity. Furthermore, when compared to the D614G variant, we found that the serum NAbs elicited by the third dose vaccine demonstrated decreased inhibition to multiple SARS-CoV-2 variants, including Gamma (0.94×), Alpha (0.91×), Delta (0.91×), Beta (0.81×), Kappa (0.81×), BA.2 (0.44×), BA.1 (0.43×), BA.3 (0.41×), BA.5 (0.35×) and BA.4 (0.33×), in cohort of 56 vaccinated individuals. Altogether, our proteomics platform proves to be an effective tool to detect broad NAbs in the population and aid in the development of future COVID-19 vaccines and vaccination strategies.

Infectious Diseases (except HIV/AIDS)

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop a high - throughput method to detect neutralizing antibodies (NAbs) against multiple variants of SARS - CoV - 2. Specifically, the researchers developed a high - throughput detection method based on flow cytometry, which can systematically evaluate neutralizing antibodies against 11 SARS - CoV - 2 variants (including D614G, Alpha, Beta, Gamma, Delta, Kappa, and the BA.1 - BA.5 sub - lineages of Omicron). This method is not only cost - effective and reliable, but also 35 times more sensitive than Luminex technology, and it can be updated as SARS - CoV - 2 evolves to include new variants for detection.

In addition, the paper also explored the application of this new method in the following aspects:
1. **Comparison with existing detection methods**: The researchers compared the results of the new method with commercial IgG serology tests, FDA - approved cPass sVNT tests, pseudovirus - based neutralization tests, and live - virus - based neutralization tests to verify its reliability and accuracy.
2. **Constructing a comprehensive map of the interaction between Spike protein and ACE2 receptor**: Using this platform, the researchers analyzed in detail the interaction between the Spike trimer protein of 11 SARS - CoV - 2 variants and the ACE2 receptor, and identified polyclonal antibodies with broad neutralizing activity.
3. **Evaluating serum neutralizing antibody levels after vaccination**: The researchers analyzed the neutralizing antibody levels in the sera of individuals after receiving the third dose of vaccine (including inactivated vaccines and recombinant subunit vaccines), and found that although the third dose of vaccine can effectively enhance protection against non - Omicron variants, the protection effect against Omicron variants is significantly reduced.

In conclusion, this paper aims to provide an efficient, sensitive, and economical tool for detecting a wide range of neutralizing antibodies in the population, thereby helping to develop future COVID - 19 vaccines and formulate more effective vaccination strategies.